WST Stock Surges 5.5% With A 5-day Winning Spree On Record Earnings
West Pharmaceutical Services (WST) – a designer and manufacturer of injectable drug delivery systems – hit a 5-day winning streak, with cumulative gains over this period amounting to 5.5%. The company’s market cap has surged by about $956 Mil over the last 5 days and currently stands at $18 Bil.
The stock has YTD (year-to-date) return of 7.5% compared to 0.5% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Rally?
[1] Q4 2025 Earnings And Sales Beat
- EPS Surprise of +11.21%
- Revenue Beat of +1.35%
- Impact: Strong Investor Confidence, Positive Market Reception
[2] New $1 Billion Share Repurchase Program
- Board Authorized Buyback
- Commitment to Capital Allocation
- Impact: Reinforced Shareholder Returns, Increased Investor Confidence
Opportunity or Trap?
Below is our take on valuation.
There are only a couple of things to fear in WST stock given its overall Strong operating performance and financial condition. This is aligned with the stock’s High valuation because of which we think it is Fairly Priced (For details, see Buy or Sell WST).
But here is the real interesting point.
You are reading about this 5.5% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Returns vs S&P 500
The following table summarizes the return for WST stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | WST | S&P 500 |
|---|---|---|
| 1D | 2.1% | -0.4% |
| 5D (Current Streak) | 5.5% | -0.4% |
| 1M (21D) | 7.8% | -1.4% |
| 3M (63D) | -9.4% | 1.7% |
| YTD 2026 | -7.5% | 0.5% |
| 2025 | -15.7% | 16.4% |
| 2024 | -6.8% | 23.3% |
| 2023 | 49.9% | 24.2% |
However, big gains can follow sharp reversals – but how has WST behaved after prior drops? See WST Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 80 S&P constituents with 3 days or more of consecutive gains and 23 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 29 | 20 |
| 4D | 33 | 0 |
| 5D | 6 | 3 |
| 6D | 4 | 0 |
| 7D or more | 8 | 0 |
| Total >=3 D | 80 | 23 |
Key Financials for West Pharmaceutical Services (WST)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $2.9 Bil | $3.1 Bil |
| Operating Income | $590.9 Mil | $636.1 Mil |
| Net Income | $492.7 Mil | $493.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $804.6 Mil | $805.0 Mil |
| Operating Income | $174.5 Mil | $175.1 Mil |
| Net Income | $140.0 Mil | $132.1 Mil |
While WST stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.